Specifications TableSubjectMedicine and DentistrySpecific subject areaImmunology, Allergology and RheumatologyType of dataData presented in tables and figuresHow data were acquiredSystematic literature searchData formatRaw and analyzed dataParameters for data collectionWe collected data regarding both included studies (methods, setting, period, systemic lupus erythematosus prevalence, characteristics, drugs and outcome) and articles where these data were published (year of publication, name of the first author, journal)Description of data collectionThe above-mentioned data were extracted from the full-texts of eligible articles and cross-checked to ensure that there was no missing informationData source locationFaculty of Medicine and Biomedical Sciences\
University of Yaoundé I\
Yaoundé\
CameroonData accessibilityAll data are included in this articleRelated research articleSystemic lupus erythematosus in Native sub-Saharan Africans: a systematic review and meta-analysis. Mickael Essouma, Jan René Nkeck, Francky Teddy Endomba, Jean Joel Bigna, Madeleine Singwe-Ngandeu, Eric Hachulla, J Autoimmun 2019 (In press) \[[@bib1]\]**Value of the Data**•This article permits an in-depth understanding of data on systemic lupus erythematosus in Native sub-Saharan Africans.•These data are beneficial for health professionals and researchers involved in systemic lupus erythematosus management and research, as well as local health authorities.•As these data inform on the burden and management of systemic lupus erythematosus in Native sub-Saharan Africans, they may be used to increase awareness for systemic lupus erythematosus in sub-Saharan Africa and serve as accurate basis for building capacity for research and management of systemic lupus erythematosus in Native sub-Saharan Africans.

1. Data description {#sec1}
===================

We herein report the pooled prevalence rates of autoantibodies ([Fig. 1](#fig1){ref-type="fig"}), the pooled frequencies of cumulative drug use ([Fig. 2](#fig2){ref-type="fig"}), the prevalence of comorbidities/complications ([Table 1](#tbl1){ref-type="table"}) and the pooled mortality rate ([Fig. 3](#fig3){ref-type="fig"}). The main search strategy used (in PUBMED) to obtain these data is displayed in [Table 2](#tbl2){ref-type="table"} and [Fig. 4](#fig4){ref-type="fig"} describes the study selection process. [Table 3](#tbl3){ref-type="table"} summarizes the characteristics of the overall 15 included studies \[[@bib2], [@bib3], [@bib4], [@bib5], [@bib6], [@bib7], [@bib8], [@bib9], [@bib10], [@bib11], [@bib12], [@bib13], [@bib14], [@bib15], [@bib16]\] whereas [Table 4](#tbl4){ref-type="table"} summarizes only the studies included in the mortality analysis \[[@bib4],[@bib6], [@bib7], [@bib8], [@bib9],[@bib14],[@bib16]\].Fig. 1Prevalence of autoantibodies in Native sub-Saharan Africans with systemic lupus erythematosus. Grey boxes represent the effect estimates (prevalence), and the horizontal bars represent the 95% confidence intervals (CI). The size of the boxes is proportional to the inverse variance. The diamonds are for the pooled effect estimates and 95% CI, and the dotted vertical line has been added to assist visual interpretation. ANA antinuclear antibodies; anti-DNA anti-deoxyribonucleic acid; anti-RNP anti-ribonucleoprotein; anti-Sm anti-Smith; anti-SSA anti-Sjogren syndrome antigen A; anti-SSB anti-Sjogren syndrome antigen B; aPL antiphospholipid antibodies; RF rheumatoid factor.Fig. 1Fig. 2Frequency of cumulative drug use among Native sub-Saharan Africans with systemic lupus erythematosus. Grey boxes represent the effect estimates (frequency), and the horizontal bars represent the 95% confidence intervals (CI). The size of the boxes is proportional to the inverse variance. The diamonds are for the pooled effect estimates and 95% CI, and the dotted vertical line has been added to assist visual interpretation.Fig. 2Table 1Prevalence of comorbidities and complications in Native sub-Saharan Africans with systemic lupus erythematosus.Table 1Complications/comorbiditiesPrevalence, range %Infections \[[@bib5],[@bib6],[@bib8],[@bib9],[@bib11],[@bib12]\]4.3--68.7Cardiovascular diseases and risk factors -Heart failure \[[@bib8]\]33.3 -Stroke \[[@bib6],[@bib10],[@bib12]\]5.1--6.8 -Peripheral vein thrombosis \[[@bib8],[@bib11]\]2--4.3 -Diabetes mellitus \[[@bib6],[@bib12]\]5.1--18.7 -Hypertension \[[@bib2],[@bib6],[@bib9]\]10.3--19.6Chronic kidney disease \[[@bib6],[@bib10],[@bib12],[@bib16]\]6.2--9.4Any aseptic osteonecrosis \[[@bib6],[@bib10]\]2.6--6.2Fig. 3Mortality rate in Native sub-Saharan Africans with systemic lupus erythematosus. Grey boxes represent the effect estimates (prevalence), and the horizontal bars represent the 95% confidence intervals (CI). The size of the boxes is proportional to the inverse variance. The diamonds are for the pooled effect estimates and 95% CI, and the dotted vertical line has been added to assist visual interpretation.Fig. 3Table 2Main search strategy for PubMed.Table 2SearchSearch terms\#1"systemic lupus erythematosus" OR "disseminated lupus erythematosus" OR SLE OR DLE OR "lupus nephritis" OR "renal SLE" OR "cutaneous lupus" OR "cutaneous DLE" OR "Lupus Erythematosus Disseminatus" OR "Libman-Sacks Disease" OR "Lupus vasculitis"\#2Africa\* OR Algeria OR Angola OR Benin OR Botswana OR "Burkina Faso" OR Burundi OR Cameroon OR "Canary Islands" OR "Cape Verde" OR "Central African Republic" OR Chad OR Comoros OR Congo OR "Democratic Republic of Congo" OR Djibouti OR Egypt OR "Equatorial Guinea" OR Eritrea OR Ethiopia OR Gabon OR Gambia OR Ghana OR Guinea OR "Guinea Bissau" OR "Ivory Coast" OR "Cote Ivoire" OR Jamahiriya OR Kenya OR Lesotho OR Liberia OR Libya OR Madagascar OR Malawi OR Mali OR Mauritania OR Mauritius OR Mayotte OR Morocco OR Mozambique OR Namibia OR Niger OR Nigeria OR Principe OR Reunion OR Rwanda OR "Sao Tome" OR Senegal OR Seychelles OR "Sierra Leone" OR Somalia OR "South Africa" OR "St Helena" OR Sudan OR Swaziland OR Tanzania OR Togo OR Tunisia OR Uganda OR "Western Sahara" OR Zaire OR Zambia OR Zimbabwe OR "Central Africa" OR "Central African" OR "West Africa" OR "West African" OR "Western Africa" OR "Western African" OR "East Africa" OR "East African" OR "Eastern Africa" OR "Eastern African" OR "North Africa" OR "North African" OR "Northern Africa" OR "Northern African" OR "South African" OR "Southern Africa" OR "Southern African" OR "sub Saharan Africa" OR "sub Saharan African" OR "subSaharan Africa" OR "subSaharan African"\#3\#1 AND \#2Fig. 4PRISMA flow chart of study selection. SLE systemic lupus erythematosus.Fig. 4Table 3Summary of studies addressing systemic lupus erythematosus in Native sub-Saharan Africans in 2008--2018.Table 3StudyDesignCountrySettingLocalityPeriod of recruitmentNumber of participantsNumber of participants with SLEClassification criteria for SLEFemales, n (%)Mean age at diagnosis of SLE, yAge range, yStudy qualityAdelowo. 2009 \[[@bib9]\]Cross-sectionalNigeriaHospital basedUrban2001--20061250661982 ACR63 (95.5)3316--60ModerateAdelowo. 2012 \[[@bib10]\]Cross-sectionalNigeriaHospital basedUrban2001--201095951982 ACR91 (95.7)33.417--55LowBudhoo. 2016 \[[@bib11]\]Cross-sectionalSouth AfricaHospital basedUrban2003--20121371371997 ACR125 (91.2)32.2NRLowDiallo. 2014 \[[@bib12]\]Cross-sectionalSenegalHospital basedUrban2010--201235351997 ACR33 (94.3)32.818--50LowDoualla. 2014 \[[@bib13]\]Cross-sectionalCameroonHospital basedUrban1999--20096485391997 ACR36 (92.3)39.219--59ModerateDubulla. 2014 \[[@bib14]\]Cross-sectionalSouth AfricaHospital basedUrban2003--200956561982 ACR and 1997 ACR51 (91.2)30.3NRLowDzifa. 2017 \[[@bib15]\]CohortGhanaHospital basedUrban2007--200951511982 ACR45 (86.5)30.414--68ModerateEkwom. 2013 \[[@bib16]\]Cross-sectionalKenyaHospital basedUrban2010--2011394131982 ACR and 1997 ACR13 (100)3412--52HighGbané-Koné. 2015 \[[@bib17]\]Cross-sectionalIvory CoastHospital basedUrban1987--201418,0761171982 ACR115 (98.3)35.812--73ModerateIba-Ba. 2009 \[[@bib18]\]Cross-sectionalGabonHospital basedUrban2004--200823231982 ACR and 1997 ACR22 (95.6)32.818--68ModerateKombate. 2008 \[[@bib19]\]Cross-sectionalTogoHospital basedUrban1991--200316161997 ACR16 (100)31.915--46LowMalemba. 2008 \[[@bib20]\]Cross-sectionalCongo, RDHospital basedUrban1988--20022370231982 ACR21 (91.3)31.8NRLowNdiaye. 2008 \[21\]Cross-sectionalSenegalHospital basedUrban1997--20061421421982 ACR and 1997 ACR125 (88)346--72LowNgaidé. 2016 \[22\]Cross-sectionalSenegalHospital basedUrban2011--201250501997 ACR46 (92)36.214--60ModerateZavier. 2014 \[23\]Cross-sectionalBeninHospital basedUrban2000--201333331997 ACR32 (97)28.816--51Low[^1]Table 4Summary of studies reporting a mortality rate in Native sub-Saharan Africans with systemic lupus erythematosus.Table 4StudyDesignCountryDuration of SLEDuration of follow upMortality rateStudy qualityDzifa. 2017 \[[@bib8]\]CohortGhanaMean 25.2 ± 31.5 months\
1--143Mean 26.1 ± 26.6 days (1--140)43.1ModerateDubula. 2014 \[[@bib7]\]Cross-sectionalSouth AfricaMedian 8 months (IQR, 1--61)3--106 days14.3LowBudhoo. 2016 \[[@bib4]\]Cross-sectionalSouth AfricaMedian 42 months (IQR, 22--88.3)Median 36 months (IQR, 12.5--68)11.7LowZavier. 2014 \[[@bib16]\]Cross-sectionalBeninNRNR12.1LowDoualla. 2014 \[[@bib6]\]Cross-sectionalCameroonNRNR5.1ModerateNdiaye. 2010 \[[@bib14]\]Cross-sectionalSenegalNR10 days-117 months2.8LowEkwom. 2013 \[[@bib9]\]Cross-sectionalKenya1--12 months1--12 months0.0High[^2]

2. Experimental design, materials, and methods {#sec2}
==============================================

•Searched databases and search strategy

A comprehensive search of PubMed, Excerpta Medica database (EMBASE), Web of Science, African Journals Online, and Global Index Medicus was conducted to identify all relevant articles published from January 1, 2008 to October 7, 2018, without any language restriction. We considered recent studies to have the current and updated clinical overview of systemic lupus erythematosus in the region. We conceived and applied a search strategy based on the combination of relevant terms. The main search strategy in PubMed was adapted for the search in the other databases. A manual search that consists of scanning reference lists of eligible studies and relevant reviews was performed to identify any studies missed during the review process or by the search strategy.

The titles and abstracts of the retrieved papers were independently screened by two investigators (ME and JRN) and the full-texts of papers deemed potentially eligible were further assessed for final inclusion. All discrepancies for study selection were resolved through discussion or with the arbitrage of a third investigator.•Criteria for considering studies for the review➢Types of studies

Observational studies including cross-sectional, case-control and cohort studies, as well as case series. We did not consider case reports, commentaries, review articles and letters to the editor.➢Types of participants

We considered studies involving African Black people (or multiethnic groups with possibility to extract information for the African Black people) living in sub-Saharan Africa regardless of the age and gender. Studies were excluded if: (1) they included multiethnic groups with no possibility to extract informations regarding only the African Black people (2) they only included a specific group of lupus patients i.e. lupus nephritis, neuropsychiatric lupus, cutaneous lupus, lupus pericarditis, lupus myocarditis, lupus in pregnant women (3) they included patients with overlapping syndromes.➢Condition

The classification for systemic lupus erythematosus was based on the 1982 American College of Rheumatology and/or revised 1997 American College of Rheumatology criteria \[[@bib17],[@bib18]\].➢Outcomes of interest

The following outcomes were analyzed: systemic lupus erythematosus prevalence; demographic, clinical and immunological characteristics of systemic lupus erythematosus; frequencies of cumulative drug use for the treatment of systemic lupus erythematosus and its complications; outcome measures of systemic lupus erythematosus.•Data extraction and management

The data were extracted by two investigators (ME and JJB) using a preconceived, piloted and standardized data abstraction form. The following data were extracted and cross-checked to ensure that there was no missing information: name of the first author, year of publication, study design, period of recruitment of the study population, setting (country, unique/multiple site\[s\]), locality (urban/rural), sampling method, systemic lupus erythematosus diagnostic criteria and the outcomes of interest.•Assessment of the methodological quality of studies

We used an adapted version of the tool developed by Hoy and colleagues \[[@bib19]\] to assess the methodological quality of included studies. Three investigators (JJB, ME and FTAE) independently ran the assessment. Discrepancies were discussed and resolved by these investigators. Cohen\'s κ statistics were used for inter-rater agreements between investigators regarding study inclusion and for the assessment of the methodological quality of the included studies.•Data synthesis and analysis

The quantitative synthesis was done using the '*meta*' packages of the R statistical software (version 3.5.1, The R Foundation for statistical computing, Vienna, Austria). We used the reference method for prevalence synthesis suggested by Barendregt and colleagues \[[@bib20]\]. The prevalence of systemic lupus erythematosus and systemic lupus erythematosus autoantibodies, the frequencies of cumulative drug use and the mortality rate were recalculated based on crude numerators and denominators provided by individual studies. To minimize the effect of studies with extremely small or extremely large prevalence estimates on the overall estimate, the variance of study-specific prevalence was stabilized with the Freeman-Tukey double arcsine transformation before pooling the data with the random effects meta-analysis model \[[@bib20]\]. Heterogeneity was assessed by the chi-square test on Cochrane\'s Q statistic, and quantified by I^2^ values. Low, moderate and high heterogeneity were considered for I^2^ values of 25%, 50% and 75% respectively. The quality of the included studies is described in [Table 3](#tbl3){ref-type="table"}. The Egger\'s test was used to assess the presence of publication bias, and a statistically significant publication bias was considered for *p*-values \< 0.1. We decided a priori that if we find publication bias, we will do no adjustment in regard, since we believed that the prevalence estimates of interest would likely be published even if they are substantially different from the previously reported estimates.
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[^1]: SLE systemic lupus erythematosus; ACR American College of Rheumatology; n number; y years; NR not reported; Congo RD Democratic Republic of the Congo.

[^2]: SLE systemic lupus erythematosus; IQR interquartile range; NR not reported.
